- Home
- ORGN vs OPTN Comparison
ORGN vs OPTN Comparison
Compare ORGN & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGN
- OPTN
- Stock Information
- Founded
- ORGN 2008
- OPTN 2010
- Country
- ORGN United States
- OPTN United States
- Employees
- ORGN N/A
- OPTN N/A
- Industry
- ORGN Major Chemicals
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- ORGN Industrials
- OPTN Health Care
- Exchange
- ORGN Nasdaq
- OPTN Nasdaq
- Market Cap
- ORGN 199.7M
- OPTN 78.4M
- IPO Year
- ORGN N/A
- OPTN 2017
- Fundamental
- Price
- ORGN $1.01
- OPTN $0.42
- Analyst Decision
- ORGN Strong Buy
- OPTN Strong Buy
- Analyst Count
- ORGN 1
- OPTN 3
- Target Price
- ORGN $3.00
- OPTN $3.00
- AVG Volume (30 Days)
- ORGN 1.2M
- OPTN 835.9K
- Earning Date
- ORGN 11-14-2024
- OPTN 11-12-2024
- Dividend Yield
- ORGN N/A
- OPTN N/A
- EPS Growth
- ORGN N/A
- OPTN N/A
- EPS
- ORGN N/A
- OPTN N/A
- Revenue
- ORGN $35,123,000.00
- OPTN $75,672,000.00
- Revenue This Year
- ORGN $10.27
- OPTN $13.42
- Revenue Next Year
- ORGN $80.25
- OPTN $52.99
- P/E Ratio
- ORGN N/A
- OPTN N/A
- Revenue Growth
- ORGN 123.12
- OPTN 5.13
- 52 Week Low
- ORGN $0.44
- OPTN $0.32
- 52 Week High
- ORGN $1.90
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- ORGN 30.46
- OPTN 35.42
- Support Level
- ORGN $0.95
- OPTN $0.39
- Resistance Level
- ORGN $1.28
- OPTN $0.57
- Average True Range (ATR)
- ORGN 0.07
- OPTN 0.05
- MACD
- ORGN -0.02
- OPTN -0.00
- Stochastic Oscillator
- ORGN 3.12
- OPTN 16.53
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.